Lead Product(s): Rexmyelocel-T
Therapeutic Area: Cardiology/Vascular Diseases Product Name: REX-001
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Deal Size: $55.9 million Upfront Cash: Undisclosed
Deal Type: Financing January 18, 2021
The new business will continue to develop Ixaka’s proprietary technologies – concentrated multi-cell therapies and targeted nanoparticle therapeutics. REX-001, Ixaka’s lead MCT product, is an autologous cell-based product in clinical development for the treatment of CLTI.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AV-101
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Incubator
Deal Size: $72.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 06, 2020
Funding will advance trials of AV-101, an inhaled, dry powder aerosol version of imatinib to treat pulmonary arterial hypertension (PAH). An oral version of imatinib showed significant efficacy in a phase 3 trial as a disease-modifying therapy for PAH.